The safety and efficacy of darbepoetin alfa (Aranesp) at 3.0 µg/kg administered every 2 weeks and recombinant human erythropoietin (rHuEPO) given as 40,000 U weekly or 150 U/kg three times weekly were evaluated by
Dianne Tomita, MPH
Advertisement
Articles by Dianne Tomita, MPH
Advertisement
Latest Updated Articles
- Every-2-Week Darbepoetin Alfa Is Comparable to rHuEPO in Treating Chemotherapy-Induced Anemia
Published: October 1st 2002 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors
2
Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer
3
Anti-TIGIT Combination Therapy Yields Positive Survival in Gastric Cancers
4
Fruquintinib Combo Prolongs PFS in Advanced/Metastatic RCC
5
